Innate Pharma SA
IDDA
Company Profile
Business description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Contact
117, Avenue de Luminy
Marseille13009
FRAT: +33 430303030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
174
Stocks News & Analysis
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.00 | 21.50 | -0.24% |
| CAC 40 | 8,233.92 | 3.51 | -0.04% |
| DAX 40 | 25,122.26 | 230.06 | 0.92% |
| Dow JONES (US) | 49,175.34 | 286.74 | -0.58% |
| FTSE 100 | 10,048.21 | 74.52 | -0.74% |
| HKSE | 26,458.95 | 251.50 | -0.94% |
| NASDAQ | 23,663.92 | 116.74 | 0.50% |
| Nikkei 225 | 51,961.98 | 556.10 | -1.06% |
| NZX 50 Index | 13,715.02 | 51.44 | 0.38% |
| S&P 500 | 6,945.84 | 1.02 | 0.01% |
| S&P/ASX 200 | 8,695.60 | 27.90 | -0.32% |
| SSE Composite Index | 4,085.77 | 2.10 | 0.05% |